2018
December 26, 2018
Sanofi: FDA Approves VAXELIS(TM), Sanofi and MSD's Pediatric Hexavalent Combination Vaccine
November 16, 2018
Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness
November 11, 2018
Sanofi: ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) was associated with fewer deaths from any cause
November 7, 2018
New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial
November 6, 2018
FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis
November 1, 2018
Sanofi and Denali Therapeutics to develop treatments for neurological and inflammatory diseases
October 16, 2018
Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps
September 28, 2018
Sanofi : FDA approves Libtayo® (cemiplimab) as first and only treatment for advanced cutaneous squamous cell carcinoma
September 12, 2018
FDA to review supplemental Biologics License Application for Praluent® (alirocumab) Injection as potential treatment to reduce major adverse cardiovascular events
September 3, 2018
Sanofi: Cablivi(TM) (caplacizumab) approved in Europe for adults with acquired thrombotic thrombocytopenic purpura (aTTP)
July 26, 2018
Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st
June 28, 2018
Sanofi : Sanofi and Advent finalize negotiations for the acquisition of Zentiva
June 19, 2018
Sanofi appoints Jean-Baptiste Chasseloup de Chatillon Executive Vice President, Chief Financial Officer
June 19, 2018
Sanofi : Sanofi completes its acquisition of Ablynx following the expiration of the Squeeze-out Procedure
June 4, 2018
Sanofi: New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma
May 21, 2018
Sanofi: New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma
May 16, 2018
Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 14, 2018
Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
May 14, 2018
Sanofi and Ablynx Announce the Successful Results of the Initial Tender Offer Period for Ablynx and Commencement of Squeeze-Out Tender Period
April 30, 2018
Sanofi: FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma
April 24, 2018
Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1
April 17, 2018
Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business
April 12, 2018
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...
April 3, 2018
Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma
April 3, 2018
Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma
March 29, 2018
Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes
March 29, 2018
Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018
March 10, 2018
Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need
March 10, 2018
Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate
March 8, 2018
Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform
March 7, 2018
Sanofi: Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report
March 6, 2018
Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director
March 2, 2018
Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma
March 1, 2018
Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx
February 23, 2018
Sanofi: Hart-Scott-Rodino waiting period expires for Sanofi's acquisition of Bioverativ
January 31, 2018
Sanofi: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment
January 19, 2018
Sanofi Appoints Dominique Carouge Executive Vice President Head of Business Transformation and Member of the Executive Committee
January 8, 2018
Sanofi and Regeneron to accelerate and expand investment for cemiplimab and dupilumab development programs
January 7, 2018
Sanofi and Alnylam enter into strategic restructuring of RNAi therapeutics rare disease alliance